PharmaCielo Ltd.

CVE: PCLO


Canadian symbol: PCLO.V
US symbol: PCLOF

Currency in CAD

Valuation Measures

Market Cap (intraday) 576.08M
Enterprise Value 372.1M
Trailing P/E N/A
Forward P/E 12.52
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)58.46
Price/Book (mrq)1.80
Enterprise Value/Revenue 355.41
Enterprise Value/EBITDA 6-2.21

Trading Information

Stock Price History

Beta (5Y Monthly) N/A
52-Week Change 3-88.38%
S&P500 52-Week Change 36.72%
52 Week High 36.2800
52 Week Low 30.5000
50-Day Moving Average 30.8017
200-Day Moving Average 31.5543

Share Statistics

Avg Vol (3 month) 3154.15k
Avg Vol (10 day) 3109.92k
Shares Outstanding 5111.88M
Float 93.09M
% Held by Insiders 116.39%
% Held by Institutions 13.35%
Shares Short (Jun. 14, 2020) 41.22M
Short Ratio (Jun. 14, 2020) 415.54
Short % of Float (Jun. 14, 2020) 4N/A
Short % of Shares Outstanding (Jun. 14, 2020) 43.63%
Shares Short (prior month May 14, 2020) 42.46M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 21:11
Last Split Date 3Jan. 17, 2019

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec. 30, 2019
Most Recent Quarter (mrq)Mar. 30, 2020

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-2,572.65%

Management Effectiveness

Return on Assets (ttm)-38.23%
Return on Equity (ttm)-67.61%

Income Statement

Revenue (ttm)1.3M
Revenue Per Share (ttm)0.01
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)643.48k
EBITDA -32.56M
Net Income Avi to Common (ttm)-33.25M
Diluted EPS (ttm)-0.3410
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)6.49M
Total Cash Per Share (mrq)0.06
Total Debt (mrq)1.5M
Total Debt/Equity (mrq)4.01
Current Ratio (mrq)2.59
Book Value Per Share (mrq)0.38

Cash Flow Statement

Operating Cash Flow (ttm)-24.58M
Levered Free Cash Flow (ttm)-21.66M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Cannabis Market and Business News

Real-time cannabis business news from hundreds of sources. Never miss the news that matters the most.




Company News Date
PCLO.V
PharmaCielo
3 weeks ago
PCLO.V
PharmaCielo
1 month ago
PCLO.V
PharmaCielo
2 months ago
PCLO.V
PharmaCielo
3 months ago
PCLO.V
PharmaCielo
3 months ago
PCLO.V
PharmaCielo
3 months ago
PCLO.V
PharmaCielo
4 months ago
PCLO.V
PharmaCielo
4 months ago
PCLO.V
PharmaCielo
5 months ago
PCLO.V
PharmaCielo
5 months ago
PCLO.V
PharmaCielo
6 months ago
PCLO.V
PharmaCielo
6 months ago
PCLO.V
PharmaCielo
7 months ago
PCLO.V
PharmaCielo
7 months ago
PCLO.V
PharmaCielo
7 months ago
PCLO.V
PharmaCielo
8 months ago
PCLO.V
PharmaCielo
8 months ago
PCLO.V
PharmaCielo
8 months ago
PCLO.V
PharmaCielo
9 months ago
PCLO.V
PharmaCielo
9 months ago
PCLO.V
PharmaCielo
9 months ago
PCLO.V
PharmaCielo
10 months ago
PCLO.V
PharmaCielo
10 months ago
PCLO.V
PharmaCielo
11 months ago
PCLO.V
PharmaCielo
11 months ago
PCLO.V
PharmaCielo
11 months ago
PCLO.V
PharmaCielo
11 months ago
PCLO.V
PharmaCielo
11 months ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago
PCLO.V
PharmaCielo
1 year ago

Currency in CAD
Earnings EstimateCurrent Qtr. (Jun 2020)Next Qtr. (Sep 2020)Current Year (2020)Next Year (2021)
No. of Analysts1111
Avg. Estimate-0.08-0.07-0.290.27
Low Estimate-0.08-0.07-0.290.27
High Estimate-0.08-0.07-0.290.27
Year Ago EPS-0.11-0.04-0.33-0.29
Revenue EstimateCurrent Qtr. (Jun 2020)Next Qtr. (Sep 2020)Current Year (2020)Next Year (2021)
No. of Analysts1122
Avg. Estimate140k1.65M25.61M94.49M
Low Estimate140k1.65M8.42M93.18M
High Estimate140k1.65M42.8M95.8M
Year Ago SalesN/A130k787k25.61M
Sales Growth (year/est)N/A1,169.20%3,154.10%269.00%
Earnings History2019-06-292019-09-292019-12-302020-03-30
EPS Est.-0.05-0.09-0.04-0.1
EPS Actual-0.11-0.04-0.13-0.07
Difference-0.060.05-0.090.03
Surprise %-120.00%55.60%-225.00%30.00%
EPS TrendCurrent Qtr. (Jun 2020)Next Qtr. (Sep 2020)Current Year (2020)Next Year (2021)
Current Estimate-0.08-0.07-0.290.27
7 Days Ago-0.08-0.07-0.290.27
30 Days Ago-0.06-0.05-0.210.2
60 Days Ago00-0.060.27
90 Days Ago000.520.21
EPS RevisionsCurrent Qtr. (Jun 2020)Next Qtr. (Sep 2020)Current Year (2020)Next Year (2021)
Up Last 7 DaysN/AN/AN/AN/A
Up Last 30 DaysN/AN/AN/AN/A
Down Last 7 DaysN/AN/AN/AN/A
Down Last 30 DaysN/AN/AN/AN/A
Growth EstimatesPCLO.VIndustrySectorS&P 500
Current Qtr.27.30%N/AN/AN/A
Next Qtr.-75.00%N/AN/AN/A
Current Year12.10%N/AN/AN/A
Next Year193.10%N/AN/AN/A
Next 5 Years (per annum)N/AN/AN/AN/A
Past 5 Years (per annum)N/AN/AN/AN/A


Insiders transactions are updated every hour.

Major Holders

Currency in CAD
Breakdown
16.39%% of Shares Held by All Insider
3.35%% of Shares Held by Institutions
4.01%% of Float Held by Institutions
7Number of Institutions Holding Shares

Top Institutional Holders

HolderSharesDate Reported% OutValue
Intercontinental Wealth Advisors, LLC12,500Dec. 30, 20190.01%38,125
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by PharmaCielo Ltd.


PharmaCielo Ltd. Closes $4.6 Million Bought Deal Offering

PharmaCielo Ltd. Closes $4.6 Million Bought Deal Offering

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FORDISSEMINATION IN THE UNITED STATES./ TORONTO, July 3, 2020 - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF) is pleased to announce that it has closed its previously announced "bought deal" offering (the "Offering") of common shares conducted by a... Read More...
PharmaCielo Ltd. Files Final Prospectus for $4 Million Bought Deal Offering

PharmaCielo Ltd. Files Final Prospectus for $4 Million Bought Deal Offering

TORONTO , June 29, 2020 - PharmaCielo Ltd. (the "Company" or "PharmaCielo") (PCLO.V) (PCLOF) is pleased to announce that it has filed a (final) short form prospectus with the securities regulatory authorities in British Columbia , Alberta , Ontario and Quebec in connection with its previously announced $4 million "bought deal" offering of... Read More...
PharmaCielo Announces Financial Results for the First Quarter Ended March 31, 2020 and Provides Operational Update

PharmaCielo Announces Financial Results for the First Quarter Ended March 31, 2020 and Provides Operational Update

PharmaCielo generated $514,409 in revenue during Q1-2020, compared to revenue of $786,901 in its full 2019 fiscal year.Pro forma cash and cash equivalents of $12.7 million 1.Processing equipment is now on-site in Rionegro; the Company expects to be in a position to begin accepting broad spectrum commercial pre-orders by the end of Q2. All... Read More...
PharmaCielo Adds Experienced Senior Leader to Executive Team

PharmaCielo Adds Experienced Senior Leader to Executive Team

 Henning von Koss – a proven 30-year veteran of the global pharmaceutical, chemical and healthcare industries – named President to focus on scaling international operations TORONTO, May 4, 2020 - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO, OTCQX: PCLOF), is pleased to announce the appointment of Mr. Henning von Koss to ... Read More...
PharmaCielo Announces Financial Results for the Fourth Quarter and Fiscal Year Ended December 31, 2019

PharmaCielo Announces Financial Results for the Fourth Quarter and Fiscal Year Ended December 31, 2019

PharmaCielo generated a record $657,000 in revenue during Q4. Generated revenue of $786,901 in fiscal 2019. $13.7 million in cash and cash equivalents at December 31, 2019 ; Subsequent to the end of the quarter, the Company closed a private placement financing for gross proceeds of approximately $8 million .All figures are in Canadian do... Read More...
PharmaCielo Provides Details for Fourth Quarter and Year-End 2019 Results Conference Call

PharmaCielo Provides Details for Fourth Quarter and Year-End 2019 Results Conference Call

TORONTO , April 29, 2020 - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO, OTCQX:PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., advised today that it will be holding its fourth quarter and fiscal 2019 financial results conf... Read More...
PharmaCielo Ltd. Announces Closing of Previously Announced $8 Million Private Placement Financing

PharmaCielo Ltd. Announces Closing of Previously Announced $8 Million Private Placement Financing

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES./ TORONTO, April 15, 2020 - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO, OTCQX: PCLOF) announced today that it has closed its previously announced "best efforts" private placement financing of 12,428,002 special warrants of... Read More...
PharmaCielo Ltd. Prices $8 Million Offering; Closing Scheduled for April 14

PharmaCielo Ltd. Prices $8 Million Offering; Closing Scheduled for April 14

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES./ TORONTO, April 6, 2020 - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO, OTCQX: PCLOF) announced today that further to its April 1 release, it has received subscriptions and subscription commitments in excess of CAD$8 millio... Read More...
PharmaCielo Announces 30,000 Kg Cannabis Extract Agreement for German Market

PharmaCielo Announces 30,000 Kg Cannabis Extract Agreement for German Market

PharmaCielo will sell a broad range of extracts – including both CBD- and THC-dominant profiles – to XPhyto Therapeutics Corp., for German market distribution Three-year agreement signed, covering a minimum delivery target of 30,000 kg, beginning mid-2020 GAP and ISO 9001:2015 Certifications Provide Key Quality Confirmation to Custo... Read More...
PharmaCielo Signs Pan-European Distribution Agreement for CBD Isolate and Broad-Spectrum CBD Oil

PharmaCielo Signs Pan-European Distribution Agreement for CBD Isolate and Broad-Spectrum CBD Oil

Company signs a three-year performance-based agreement with CBD Export GlobalDistribution channel covers the entire EU-zone as well as Switzerland and LichtensteinShipments to commence in 2020 with increasing volumes during duration of AgreementTORONTO and RIONEGRO, Colombia , Jan. 24, 2020 - PharmaCielo Ltd. ("PharmaCielo" or the "Compan... Read More...
PharmaCielo to Hold Conference Call to Review Third Quarter 2019 Financial Results

PharmaCielo to Hold Conference Call to Review Third Quarter 2019 Financial Results

TORONTO , Nov. 25, 2019 - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO, OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., announces today that it will host a conference call on Monday, November 25 th, 2019, at 5:00 p.... Read More...
PharmaCielo Announces Financial Results for the Three and Nine Months Ended September 30, 2019

PharmaCielo Announces Financial Results for the Three and Nine Months Ended September 30, 2019

"All-in" cost to produce dried cannabis of $0.04i per gram in Q3 – 20% better than targeted. Net loss significantly reduced to $3.8 million compared to $10.7 million in Q2-2019. Well capitalized with cash and short-term investments of $20.7 million as of September 30, 2019. Initiating commercial sales – Completed sales negotiation... Read More...
PharmaCielo Announces RSU Grant

PharmaCielo Announces RSU Grant

TORONTO, Nov. 8, 2019 - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO, OTC:PHCEF) today announced that on November 5, 2019 (the "Grant Date") the board of directors approved and granted 25,000 restricted share units ("RSUs") to Carlos Manuel Uribe, a director of the Company, which all vest on the Grant Date. Each ... Read More...
PharmaCielo Announces Creso Pharma's Receipt of Australian Court Approval to Convene Meeting of Shareholders

PharmaCielo Announces Creso Pharma’s Receipt of Australian Court Approval to Convene Meeting of Shareholders

PharmaCielo's acquisition of Creso Pharma will establish a global medicinal cannabis company, positioned to rapidly develop new markets and grow sales in the expanded footprint served by the combined company. TORONTO, Oct. 2, 2019 - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO), is pleased to announce key develop... Read More...
PharmaCielo Enters the U.S. with $3 Million Q4 Sales Agreement and Completes Introductory Shipments to Multi-state Distributor General Extract LLC

PharmaCielo Enters the U.S. with $3 Million Q4 Sales Agreement and Completes Introductory Shipments to Multi-state Distributor General Extract LLC

2019 market introduction revenues projected at minimum $3 million CDN Agreement covers sales and distribution of medicinal CBD isolate in multiple US states commencing in 2019 with allowance for renewal and volume expansion in 2020 Introductory shipments, meeting CBD isolate requirements of 2018 Farm Bill, successfully completed C... Read More...
PharmaCielo Expands Further Into Latin America With Sales Agreement to Supply CBD Extracts, Oils and Veterinary Products to Laboratorios Adler

PharmaCielo Expands Further Into Latin America With Sales Agreement to Supply CBD Extracts, Oils and Veterinary Products to Laboratorios Adler

The four-and-a-half-year agreement with option for renewal signals PharmaCielo's foray into the high-growth veterinary CBD treatment and wellness market. This is also the first collaboration between PharmaCielo and Creso Pharma that includes sub-contracting to Creso the responsibility for manufacture and supply of Creso's veter... Read More...
PharmaCielo Achieves Twelvefold Increase in Dried Cannabis Processing Capacity to Meet Global Demand for Medicinal Oil Extracts

PharmaCielo Achieves Twelvefold Increase in Dried Cannabis Processing Capacity to Meet Global Demand for Medicinal Oil Extracts

Investment of CDN$4 million expands Colombian processing capabilities twelvefold through addition of high-volume extraction equipment and proprietary techniques Annual extraction capacity increased to 265 tonnes, as Company has begun processing inventory of 18 tonnes of dried flower currently in storage Increased production of oil e... Read More...
PharmaCielo First to Receive Colombian Government Export Approval for Commercial Sale of CBD Isolate

PharmaCielo First to Receive Colombian Government Export Approval for Commercial Sale of CBD Isolate

Completion of commercial export permit process clears the way for PharmaCielo to initiate shipment of its medicinal-grade CBD extracts to wholesale distributors and product manufacturers CBD isolate to be exported holds a purity certificate of analysis (COA) of 99+% and meets all other strict quality control standard requirements TOR... Read More...
PharmaCielo Colombia Holdings S.A.S. Appoints Andres Felipe Botero as Chief Operations Officer

PharmaCielo Colombia Holdings S.A.S. Appoints Andres Felipe Botero as Chief Operations Officer

Mr. Botero brings nearly two decades of domestic and international operational experience with industry giant Philip Morris International, most recently as Director of Operations for the Andean Cluster The appointment will help drive the growth of the Company's production capacity as it readies to feed global supply channels RIONEGRO... Read More...
PharmaCielo Gears Up for U.S. Market Demand, Enlists Former Congressman and Medical Cannabis Advocate Dana Rohrabacher as a Special Advisor

PharmaCielo Gears Up for U.S. Market Demand, Enlists Former Congressman and Medical Cannabis Advocate Dana Rohrabacher as a Special Advisor

Rohrabacher is a longstanding advocate for the legalization of medical cannabis Rohrabacher spearheaded historic U.S. legislation that protects medical cannabis patients TORONTO, May 29, 2019 - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO), the Canadian parent of Colombia's premier cultivator and producer of medi... Read More...
PharmaCielo Announces Results of AGM

PharmaCielo Announces Results of AGM

TORONTO and RIONEGRO, Colombia, May 24, 2019 - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., is pleased to announce the results of the Company's annual general and special meet... Read More...
PharmaCielo Announces Its Financial Results for the Fourth Quarter and Fiscal Year 2018

PharmaCielo Announces Its Financial Results for the Fourth Quarter and Fiscal Year 2018

PharmaCielo expects to begin commercial sales in 2019. Oil processing facility is on track for commercial operation and GMP certification during Q3-2019, enabling large-scale production and sale of refined cannabis oil. Currently, 10 hectares are under active cultivation, expanding to 20 hectares (~2.15 million square feet) by year... Read More...
PharmaCielo Doubles Its Portfolio of Proprietary Cannabis Strains Approved for Colombia's Cultivar Registration

PharmaCielo Doubles Its Portfolio of Proprietary Cannabis Strains Approved for Colombia’s Cultivar Registration

Adds 10 new THC-dominant strains to previously approved group, including unique 1:1 ratio strainCompany holds the largest and most diversified portfolio of cultivar-registered strains in ColombiaPharmaCielo has 10 additional strain applications awaiting approvalTORONTO and RIONEGRO, COLOMBIA , March 29, 2019 - PharmaCielo Ltd. ("PharmaCie... Read More...
Coming Soon.
SymbolExchangePriceChangeAs of
PCLO.V
TSX Venture Exchange (former Canadian Ventures Exchange)
TSX Venture Exchange (former Canadian Ventures Exchange)0.68CAD--
PCLOF.PK
OTC MARKETS GROUP L1 AND L2
OTC MARKETS GROUP L1 AND L20.53USD+8.16%
PCLO.GO
Canadian Securities Exchange/PURE - CSE Listed & Other Canadian Listed Securities
Canadian Securities Exchange/PURE - CSE Listed & Other Canadian Listed Securities0.75CAD0.00%
PCLOF.PQ
OTC MARKETS GROUP L1 AND L2
OTC MARKETS GROUP L1 AND L20.53USD+3.92%

Delayed data (1h)
NameAgePositionAppointed
Simon Anthony Christopher Langelier
Chairman of the Board
--Chairman of the Board--
David Attard
Chief Executive Officer, Director
--Chief Executive Officer, Director--
Scott Laitinen
Chief Financial Officer
--Chief Financial Officer--
David Gordon
Chief Corporate Officer
--Chief Corporate Officer--
Delon Human
Global Head, Health and Innovation
--Global Head, Health and Innovation--
Douglas H. Bache
Director
--Director--
Matteo Lorenzo Pellegrini
Director
--Director--
Carlos Manuel Uribe
Director
--Director--
Henning von Koss
Director
--Director--


Share this page